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PGI10
PHARMACY DISPENSING PATTERNS,
COST AND HEALTHCARE UTILIZATION:
A STUDY OF LANSOPRAZOLE
Johnson ML, Beyth R
Houston Center for Quality of Care and Utilization Studies,
Houston,TX, USA
In the Department of Veterans Affairs (VA) expenditures
for pharmaceuticals were nearly $2Billion or 11% of 
the total budget in FY1999 (October 1998–September
1999), and have been increasing from 11 to 21 percent
annually.
OBJECTIVE: To develop methods to examine pharmacy
dispensing patterns and to determine the association with
healthcare costs and utilization.
METHODS: 24,765 patients who received a prescription
of Lansoprazole during FY1999 at any of the 10 hospi-
tals one regional network were studied. Dispensing pat-
terns leading to overlaps (overﬁlling) and gaps (underuse),
deﬁned as a dispensing at least 10 days before or after,
respectively, the days supply of the prior dispensing
ended, were identiﬁed. Outpatient visit and hospitaliza-
tion rates were calculated for 6 months of follow-up and
tested for associations with overﬁlling and underuse.
Source of dispensing, Mail (M) or Window (W), and days
of supply were examined to gain insight into factors that
contribute to inefﬁcient dispensing patterns.
RESULTS: 49.7% of all patients experienced an overlap,
51.1% experienced a gap, and 27.2% experienced both.
The net cost associated with overﬁlling for 6 months of
follow-up was $392,616, or 7.9% of the total 6-month
cost of approximately $5Million for Lansoprazole. Gaps
and overlaps in medications were associated with higher
utilization of both inpatient and outpatient services. A
mix of MW dispensing pairs more often resulted in gaps
or overlaps than concordant pairs (MM or WW). 10.7%
of dispensings were for days supply of 31-to-90 days;
however, 49.2% of 31-to-90 day prescriptions resulted in
overlaps.
CONCLUSION: Overﬁlling is estimated to be 8% of total
costs for Lansoprazole, and is associated with increased
utilization. Further research is needed to determine how
pharmacy dispensing patterns impact healthcare costs and
outcomes. With increasing pharmaceutical costs and
emphasis on patient safety, research into efﬁcient delivery
and timely receipt of medication is important.
GASTROINTESTINAL DISEASES/DISORDERS—
Quality of Life Presentations
PGI11
EFFECT OF RABEPRAZOLE ON HEALTH-
RELATED QUALITY OF LIFE (HRQOL) IN
PATIENTS REPORTING INEFFECTIVE RELIEF
WITH PRIOR OMEPRAZOLE OR
LANSOPRAZOLE THERAPY
Girts TK, Siddique RM, Jokubaitis LA
Janssen Pharmaceutica Inc.,Titusville, NJ, USA
OBJECTIVES: The purpose of this study is to evaluate
the effect of rabeprazole (RAB) 20mg daily on HRQoL
among patients that participated in the Future of Acid
Suppression Therapy (F.A.S.T.) trial. The F.A.S.T. trial
was an open-label, multicenter, 8-week study measuring
the effectiveness of RAB in 2579 patients with erosive
gastroesophageal reﬂux disease (GERD). The two sub-
populations in this analysis were patients reporting 
prior ineffective relief with omeprazole (OME) (n = 290)
or lansoprazole (LAN) (n = 212) within 3 months of study
entry.
METHODS: The SF-36 health survey was used to
measure HRQoL in patients at baseline and after 8 weeks
of treatment with RAB. The SF-36 includes eight scales:
Physical Functioning (PF), Role-Physical (RP), Bodily
Pain (BP), General Health (GH), Vitality (VT), Social
Functioning (SF), Role-Emotional (RE) and Mental
Health (MH). Two summary measures, Physical Health
Component Summary (PCS) and Mental Health Compo-
nent Summary (MCS), are produced from aggregating the
most highly related scales. This study used paired t-tests
to compare baseline to 8-week scores for signiﬁcant
changes in HRQoL.
RESULTS: There were 248 OME and 180 LAN patients
that completed a SF-36 survey at baseline and 8-weeks.
All scales and summary scores in both groups had a sta-
tistically signiﬁcant (p < 0.05) mean increase after 8 weeks
of treatment on RAB except for PF in patients having
prior ineffective OME therapy. For both groups, the fol-
lowing scales had a increase in score of greater than ﬁve
points from baseline to 8-weeks which is considered clin-
ically signiﬁcant: RP, BP, VT, SF, and RE. In addition the
group of patients having prior ineffective OME therapy
also had a clinically signiﬁcant increase in MH.
CONCLUSIONS: Overall, RAB showed signiﬁcant
improvements in HRQoL among patients with erosive
GERD who reported ineffective relief with prior OME or
LAN therapy.
PGI12
FACTOR STRUCTURE AND FURTHER
VALIDATION OF THE GASTROESOPHAGEAL
REFLUX DISEASE (GERD) SYMPTOM
ASSESSMENT SCALE
Damiano A1, Siddique R2, Xu X1, Imeokparia A1
1Covance Health Economics and Outcomes Services Inc,
Gaithersburg, MD, USA; 2Janssen Pharmaceutica Inc,Titusville,
NJ, USA
OBJECTIVES: The GERD Symptom Assessment Scale
(GSAS) measures distress associated with 15 GERD-
related symptoms. The purpose of this study was to 
evaluate its factor structure.
METHODS: The GSAS was collected at baseline and four
weeks following treatment in two randomized, placebo-
controlled trials of rabeprazole for moderately severe
GERD. Patients rated how distressed they were by each
symptom from 0 (no symptom or not at all distressed) to
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3 (very distressed). We conducted a principal components
analysis (PCA) of baseline responses. Overall and sub-
scale scores were computed as average distress scores
across relevant symptoms. We assessed internal consis-
tency reliability using Cronbach’s alpha. We assessed
reproducibility by evaluating the intraclass correlation
coefﬁcient (ICC) between baseline and follow-up scores
among patients reporting no change in overall symptom
severity (n = 45). We compared mean GSAS scores across
subgroups of patients with varying levels of symptom
severity at baseline and varying degrees of heartburn relief
at follow-up using t-tests.
RESULTS: The mean (sd) age of the 278 patients was
43.6 (11.9) years, and most were female (65%) and 
Caucasian (77%). The PCA and reliability estimates 
suggested three subscales: gastrointestinal symptoms (GI),
regurgitation and heartburn (RHB), and upper respira-
tory manifestations (URM). The subscale and overall
scores were reliable (Cronbach’s alpha, ICC): GI = 0.81,
0.81; RHB = 0.79, 0.80; URM = 0.73, 0.72; Overall =
0.87, 0.85. Mean baseline overall and subscale scores
were at least 10% poorer among patients reporting
greater symptom severity (p < 0.01). Patients reporting
complete heartburn relief at follow-up reported 13% to
16% greater improvements in overall, GI, and RHB
scores than patients who did not experience complete
relief (p < 0.001).
CONCLUSIONS: This study conﬁrmed the reliability
and validity of the overall GSAS score. Further, re-
searchers may want to consider analyzing the GI, URM,
and RHB subscale scores as secondary indicators of
symptom distress.
GASTROINTESTINAL DISEASES/DISORDERS—
Health Policy Presentations
PGI13
USE OF NONSTEROIDAL ANTI-
INFLAMMATORY AGENTS IN PATIENTS AT
HIGH RISK FOR GASTROINTESTINAL SIDE
EFFECTS IN A VETERANS AFFAIRS MEDICAL
CENTER
Harris CL, Raisch DW
VA Cooperative Studies Program, Albuquerque, NM, USA
The risk of signiﬁcant injury to the gastrointestinal (GI)
tract from nonsteroidal anti-inﬂammatory drugs
(NSAIDs) has been well established. Patients concurrently
using warfarin or who have had a prior serious hospital
GI event are considered to be at high risk. In 2000, the
Veterans Affairs (VA) implemented treatment criteria for
the use of NSAIDs including cyclooxygenase–2 (COX-2)
inhibitors. The high-risk criteria-based therapy is sal-
salate, non-selective NSAID plus a proton pump inhibitor
(PPI), high-dose famotidine, or misoprostol or a COX-2
inhibitor.
OBJECTIVES: The purpose of this study was to assess
the level of criteria-based NSAID prescribing in high risk
patients at the New Mexico VA Healthcare System.
METHODS: Patients with concurrent prescriptions for
an NSAID and warfarin or previous hospital GI event
were identiﬁed utilizing VA databases. Current therapy
was compared to criteria-based therapy to assess level of
implementation.
RESULTS: Out of 7,625 NSAID users, 184 patients were
identiﬁed: concurrent warfarin (n = 98), prior hospital GI
event (n = 84), and concurrent warfarin with a previous
hospital GI event (n = 2). Fifty-eight percent were 
over the age of 65. The NSAIDs prescribed were ibu-
profen (42.4%), naproxen (20.1%), etodolac (16.8%),
indomethacin (8.2%), salsalate (5.4%), piroxicam
(3.3%), COX-2 inhibitors (2.1%), and sulindac (1.6%).
Criteria-based therapy was prescribed for 22% of
patients. Only 12% of warfarin patients and 33% of pre-
vious hospital GI event patients were prescribed criteria-
based therapy. Of the patients prescribed a non-selective
NSAID (n = 139), there were only 19% prescribed a 
criteria-based GI protective medication.
CONCLUSIONS: In this study, few patients, at high-risk
for GI complications due to NSAIDs, received criteria-
based therapy.
PGI14
ASSESSMENT OF USE OF THE VETERANS
AFFAIRS’ CRITERIA FOR NONSTEROIDAL 
ANTI-INFLAMMATORY AGENTS
Harris CL, Raisch DW
VA Cooperative Studies Program, Albuquerque, NM, USA
The risk of signiﬁcant injury to the gastrointestinal (GI)
tract from nonsteroidal anti-inﬂammatory drugs
(NSAIDs) has been well established. The Veterans’ Affairs
(VA) implemented treatment criteria for the use of
NSAIDs including the new class of drugs, cyclooxyge-
nase–2 (COX-2) inhibitors. These criteria utilize a self-
administered Gastrointestinal Risk Assessment Tool (GI
Score), developed from the Arthritis, Rheumatism, and
Aging Medical Information System (ARAMIS) database,
to assess risk. This tool generates a composite score 
used to predict the 1-year risk level, level 1 (no risk) to
level 4 (substantial risk), for the potential of an NSAID-
associated GI event.
OBJECTIVES: The purpose of this study was to assess
the risk level and the level of implementation of the VA
criteria.
METHODS: The GI score was used to assess the patient’s
risk level calculated on the basis of data from VA demo-
graphic, prescription, hospitalization, clinic visits, and
active problem lists databases. Current therapy was 
compared to criteria-based therapy to assess level of
implementation.
RESULTS: There were 7,625 NSAID users in the New
Mexico VA Healthcare System: 86 previous hospitalized
GI event patients, 100 concurrent warfarin therapy
patients, 223 corticosteroid therapy patients, and 205
rheumatoid arthritis patients. Thirty-six percent of the 
VA patients were over the age of 65. The most commonly
